SENS Senseonics Holdings

Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference

Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference

GERMANTOWN, Md., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming TD Cowen 45th Annual Health Care Conference, being held in Boston, MA.

TD Cowen 45th Annual Health Care Conference

Format: Corporate overview and one-on-one meetings

Date: Tuesday, March 4, 2025

Time: 3:10 pm ET

Webcast:

Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at .

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Senseonics Investor Contact

Jeremy Feffer

LifeSci Advisors





EN
13/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Senseonics Holdings

 PRESS RELEASE

Senseonics Announces Pricing of $50 Million Public Offering of Common ...

Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 100,000,000 shares of common stock at a price to the public of $0.50 per share of common stock. The gross proceeds to Senseonics from the offering, bef...

 PRESS RELEASE

Senseonics Announces Commencement of $50 Million Public Offering of Co...

Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the proposed offering, Senseonics al...

 PRESS RELEASE

Senseonics Holdings, Inc. Reports First Quarter Financial Results

Senseonics Holdings, Inc. Reports First Quarter Financial Results Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor (CGM); twiist with Eversense 365 launch expected in Q3 GERMANTOWN, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today r...

 PRESS RELEASE

Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Releas...

Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern Time GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Management will hold a conference call to review the Company’s...

 PRESS RELEASE

Sequel Med Tech and Senseonics Integrate Technologies to Create First ...

Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM) twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system twiist with Eversense 365 launch expected in Q3 MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch